ArticleCurrent medical science2025
TM4SF1 as a Prognostic Biomarker and Therapeutic Target in Cervical Cancer.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveAccumulating evidence suggests that transmembrane 4 L6 family member 1 (TM4SF1) is associated with the development of various cancers; yet comprehensive studies on TM4SF1 in cervical cancer are lacking. Therefore, we aimed to evaluate the prognostic value of TM4SF1 in cervical cancer, elucidate its potential oncogenic functions in this disease, and further explore its feasibility as a therapeutic target.
methodsThe expression profiles and clinical information of cervical cancer patients were obtained from The Cancer Genome Atlas (TCGA) database. The expression levels of TM4SF1 were compared between cervical cancer and normal cervical tissues using the Wilcoxon rank-sum test. Kaplan-Meier analysis was employed to assess the prognostic value of TM4SF1. Furthermore, functional enrichment analyses were performed to explore the associated signaling pathways and biological functions. The methylation status of TM4SF1 was analyzed using the UALCAN and MethSurv databases. In addition, in vitro experiments were conducted to preliminarily validate the role and mechanisms of TM4SF1 in cervical cancer.
resultsTM4SF1 was overexpressed in nearly all tumors, and its overexpression was associated with poor prognosis in cervical cancer. Moreover, the correlation between TM4SF1 expression and the expression of immune cell infiltration markers and immune checkpoint genes suggested that it had potential applications in cancer immunotherapy. Western blot analysis and immunohistochemistry revealed significantly elevated protein levels of TM4SF1 in cervical cancer tissues and cells. Further studies revealed that the knockdown of TM4SF1 significantly inhibited the migration, invasion, and epithelial-mesenchymal transition (EMT) of HeLa and SiHa cells, as well as promoted their apoptosis.
conclusionTM4SF1 may serve as a potential prognostic biomarker and therapeutic target for cervical cancer.
Indexed as
Identifiers
41182643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.